A panelist discusses how structured assessment tools like the itch Numeric Rating Scale, combined with a flexible, patient-centered approach to topical therapies—including both traditional steroids and newer non-steroidal agents—can improve atopic dermatitis management in primary care by enhancing treatment tracking, patient education, and access to appropriate care.
A panelist discusses how diagnosing and assessing atopic dermatitis across diverse skin types in primary care requires visual familiarity, patient-reported outcomes like itch severity, and practical tools such as body surface area and Investigator’s Global Assessment, emphasizing that effective management depends on combining clinical observation with patient experience.
A panelist discusses how recognizing the diverse presentations and patient demographics of atopic dermatitis—especially adult-onset cases and common mimics like scabies—is essential for accurate diagnosis and management in primary care, with an emphasis on clinical assessment over biopsy and the importance of cultural competence in dermatologic evaluation.
A panelist discusses how a fresh approach to atopic dermatitis management in primary care emphasizes early recognition, appropriate use of new topical therapies, and collaboration with dermatologists to address the disease’s diverse presentations and chronic course.
An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences.
An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences.
An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences.
Rates of amputation in Black Americans with peripheral arterial disease are 3-times higher than that of their White counterparts. Dr Fakorede, discusses, here.
The increase in stool-based CRC testing is a logical trend, Hendrick said in an interview, given the convenience plus the 2 million younger adults now eligible for screening.
An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences.